Condition 1: COVID-19. Condition 2: Acute Kidney Injury. Condition 3: Chronic Kidney Disease. Coronavirus infection, unspecified Acute kidney failure Chronic kidney disease (CKD)
Conditions
Interventions
Intervention 1: Intervention group: This group receives 200 mg Remdesivir on the first day as an intravenous infusion and then 100 mg daily up to 5 doses. Intervention 2: Control group: In this group,
Sponsors
Men's Health and Reproductive Health Research Center(MHRHRC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with acute or chronic renal failure, with a definitive diagnosis of Covid 19, over the age of 18 years, and lung involvement above 20% or hypoxia (oxygen saturation less than or equal to 93%) Definitive diagnosis of Covid 19 Over the age of 18 years Pulmonary involvement caused by Covid 19
Exclusion criteria
Exclusion criteria: Previous history of COVID-19 infection and heart disease and receiving Remdesivir History of lung disease History of liver disease (such as hepatitis, cirrhosis) History of underlying diseases other than renal impairment that contribute to poor prognosis and increased mortality following coronary heart disease (eg, heart failure, active cancer, advanced diabetes with severe macrovascular and microvascular complications, previous stroke) Immunosuppressive use except in the field of kidney transplantation Prohibition of Ramdesivir (except low GFR)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Red blood cell count. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Cell counter.;Platelet count. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Cell counter.;White blood cell count. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Cell counter.;Medium platelet volume. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Cell counter.;Erythrocyte Sedimentation Rate. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;CRP. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;AST. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;ALT. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;International Normalized Ratio(INR). Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;Bilirubin. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;Alkaline phosphatase. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;Cratinin. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;O2 Saturation. Timepoint: The beginning of the visit, While receiving Remdesivir, after received Remdesivir. Method of measurement: Laboratory Kit.;Lymphocyte count. Timepoint: The beginning of the v | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahboobeh Freidoon
Shahid Beheshti University of Medical Sciences
Outcome results
None listed